Matthias Gehringer

2.0k total citations · 2 hit papers
43 papers, 1.4k citations indexed

About

Matthias Gehringer is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Matthias Gehringer has authored 43 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 20 papers in Organic Chemistry and 14 papers in Oncology. Recurrent topics in Matthias Gehringer's work include Click Chemistry and Applications (10 papers), Protein Degradation and Inhibitors (8 papers) and Cytokine Signaling Pathways and Interactions (7 papers). Matthias Gehringer is often cited by papers focused on Click Chemistry and Applications (10 papers), Protein Degradation and Inhibitors (8 papers) and Cytokine Signaling Pathways and Interactions (7 papers). Matthias Gehringer collaborates with scholars based in Germany, Switzerland and United States. Matthias Gehringer's co-authors include Stefan Laufer, Pierre Koch, Michael Förster, Ricardo A. M. Serafim, Silke M. Bauer, Karl‐Heinz Altmann, Stefan Knapp, A. Chaikuad, Kamran Ghoreschi and Julia Holstein and has published in prestigious journals such as Angewandte Chemie International Edition, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Matthias Gehringer

38 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology

2018 502 citations Matthias Gehringer, Stefan Laufer Journal of Medicinal Chemistry profile →
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update

2024 77 citations Ricardo A. M. Serafim, Matthias Gehringer et al. Journal of Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthias Gehringer Germany	19	807	614	306	186	96	43	1.4k
Philip Lienau Germany	21	766 0.9×	433 0.7×	468 1.5×	111 0.6×	53 0.6×	37	1.4k
Richard A. Norman United Kingdom	18	1.0k 1.3×	325 0.5×	269 0.9×	165 0.9×	83 0.9×	26	1.5k
Neil Moss United States	19	1.1k 1.3×	623 1.0×	362 1.2×	313 1.7×	97 1.0×	34	1.7k
Richard Sedrani Switzerland	16	783 1.0×	343 0.6×	237 0.8×	149 0.8×	91 0.9×	23	1.6k
Matthew W. D. Perry Sweden	19	834 1.0×	513 0.8×	179 0.6×	147 0.8×	36 0.4×	34	1.4k
John W. Ellingboe United States	25	893 1.1×	906 1.5×	122 0.4×	137 0.7×	97 1.0×	54	1.8k
Douglas R. Dougan United States	19	918 1.1×	378 0.6×	293 1.0×	152 0.8×	27 0.3×	32	1.6k
Armando G. Villaseñor United States	17	537 0.7×	355 0.6×	139 0.5×	76 0.4×	53 0.6×	21	1.1k
Stuart L. Emanuel United States	24	763 0.9×	765 1.2×	565 1.8×	149 0.8×	43 0.4×	42	1.9k
Joseph Schoepfer Switzerland	24	1.5k 1.9×	532 0.9×	470 1.5×	209 1.1×	34 0.4×	43	2.0k

Countries citing papers authored by Matthias Gehringer

Since Specialization

Citations

This map shows the geographic impact of Matthias Gehringer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Gehringer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Gehringer more than expected).

Fields of papers citing papers by Matthias Gehringer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias Gehringer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Gehringer. The network helps show where Matthias Gehringer may publish in the future.

Co-authorship network of co-authors of Matthias Gehringer

This figure shows the co-authorship network connecting the top 25 collaborators of Matthias Gehringer. A scholar is included among the top collaborators of Matthias Gehringer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthias Gehringer. Matthias Gehringer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Serafim, Ricardo A. M. & Matthias Gehringer. (2025). High-Quality In Vivo Chemical Probes for Protein Kinases Disclosed in 2024. ACS Pharmacology & Translational Science. 8(8). 2401–2414.

2.

Serafim, Ricardo A. M., et al.. (2025). Screening of Covalent Kinase Inhibitors Yields Hits for Cysteine Protease USP7 / HAUSP. Drug Design Development and Therapy. Volume 19. 2253–2284.

3.

Lämmerhofer, Michael, et al.. (2024). Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53. Drug Design Development and Therapy. Volume 18. 2653–2679. 9 indexed citations

4.

Rudalska, Ramona, Martin P. Schwalm, B.J. Wagner, et al.. (2024). Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on S _N Ar Electrophiles. Journal of Medicinal Chemistry. 67(8). 6549–6569. 14 indexed citations

5.

Pan, Yufeng, Benedict‐Tilman Berger, Michael Förster, et al.. (2024). Probing the Protein Kinases′ Cysteinome by Covalent Fragments. Angewandte Chemie International Edition. 64(8). e202419736–e202419736. 5 indexed citations

6.

Pan, Yufeng, Benedict‐Tilman Berger, Michael Förster, et al.. (2024). Untersuchung der Adressierbarkeit des Cysteinoms der Proteinkinasen durch Kovalente Fragmente. Angewandte Chemie. 137(8). 1 indexed citations

7.

Serafim, Ricardo A. M., et al.. (2024). Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update. Journal of Medicinal Chemistry. 67(10). 7668–7758. 77 indexed citations breakdown →

8.

Serafim, Ricardo A. M., et al.. (2023). Covalent chemical probes for protein kinases. 3. 100040–100040. 14 indexed citations

9.

Gehringer, Matthias, Marı́a Méndez, Julien Lefranc, et al.. (2023). Back in Person: Frontiers in Medicinal Chemistry 2023. ChemMedChem. 18(19).

10.

Saad, Hamada, Matthias Gehringer, Markus Krämer, et al.. (2021). Nocathioamides, Uncovered by a Tunable Metabologenomic Approach, Define a Novel Class of Chimeric Lanthipeptides. Angewandte Chemie. 133(30). 16608–16615. 5 indexed citations

11.

Saad, Hamada, Matthias Gehringer, Markus Krämer, et al.. (2021). Nocathioamides, Uncovered by a Tunable Metabologenomic Approach, Define a Novel Class of Chimeric Lanthipeptides. Angewandte Chemie International Edition. 60(30). 16472–16479. 23 indexed citations

12.

Alves, Alessandro Menna, et al.. (2021). Current jakinibs for the treatment of rheumatoid arthritis: a systematic review. Inflammopharmacology. 29(3). 595–615. 12 indexed citations

13.

Scherr, Nicole, Marie‐Thérèse Ruf, Jean‐Pierre Dangy, et al.. (2017). The Macrolide Toxin Mycolactone Promotes Bim-Dependent Apoptosis in Buruli Ulcer through Inhibition of mTOR. ACS Chemical Biology. 12(5). 1297–1307. 53 indexed citations

14.

Gehringer, Matthias & Stefan Laufer. (2017). Click Chemistry: Novel Applications in Cell Biology and Drug Discovery. Angewandte Chemie International Edition. 56(49). 15504–15505. 27 indexed citations

15.

Förster, Michael, Matthias Gehringer, & Stefan Laufer. (2017). Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting. Bioorganic & Medicinal Chemistry Letters. 27(18). 4229–4237. 32 indexed citations

16.

Gehringer, Matthias & Stefan Laufer. (2017). Neue Anwendungen der Klick‐Chemie in Zellbiologie und Wirkstoffentwicklung. Angewandte Chemie. 129(49). 15709–15711. 8 indexed citations

17.

Ostrovskyi, Dmytro, Tobias Rumpf, Alexandre Lumbroso, et al.. (2016). Tofacitinib and Analogs as Inhibitors of the Histone Kinase Prk1 (Pkn1). Future Medicinal Chemistry. 8(13). 1537–1551. 9 indexed citations

18.

Förster, Michael, A. Chaikuad, Silke M. Bauer, et al.. (2016). Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket. Cell chemical biology. 23(11). 1335–1340. 91 indexed citations

19.

Gehringer, Matthias, et al.. (2015). c-JunN-terminal kinase inhibitors: a patent review (2010 – 2014). Expert Opinion on Therapeutic Patents. 25(8). 849–872. 45 indexed citations

20.

Gehringer, Matthias, et al.. (2014). 2-(3-{(3R,4R)-4-Methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl}oxetan-3-yl)acetonitrile monohydrate. Acta Crystallographica Section E Structure Reports Online. 70(4). o382–o383.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact